An Analysis of the Psychiatric Pipeline

| September 30, 2010 | 0 Comments

by Jeffrey Ventimiglia, BSE, and Amir H. Kalali, MD
Mr. Ventimiglia is an analyst in Clinical Strategy and Solutions, Quintiles, Inc., Durham, North Carolina; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc; Professor of Psychiatry, University of California, San Diego, California.

Psychiatry (Edgemont) 2010;7(9):14–15

The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Tags: , , , , , ,

Category: Anxiety Disorders, Child Adol Mental Disorders, Drug Development, Mental Disorders, Mood Disorders, Past Articles, Psychiatry, Schizophrenia, Trend Watch

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.